Immunotherapy in acute arsenic poisoning

Jerrold B. Leikin*, Robin G Leikin, Michael A. Evans, Stanley Wiener, Daniel O. Hryhorczuk

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We investigated the use of immunotherapy on the treatment of sodium arsenite toxicity. Female balb/c mice injected with arsanilic acid conjugated to a carrier protein (ovalbumin) were shown to produce antibodies (arsenic reactive serum, ARS) reactive with arsanilic acid and sodium arsenite. Serum was tested for anti-ARS antibodies using a solid phase radioimmunoassay. The antisera bound to ARS conjugated to the synthetic copolymer glutamic acid60 tyrosine30 when diluted as high as 1:4096. Following multiple injections of 100 μg of arsanilic acid - ovalbumin compound, mortality on injection with sodium arsenite 0.87 mg/kg i.p. one week later decreased to 0 deaths in 22 pretreated mice vs 9 deaths in 29 untreated mice (31% mortality; p < 005). No decrease in mortality was noted at higher challenges (1.15 mg/kg) of sodium arsenite. Antisera from pretreated mice was injected 0.1 cc i.p. into 12 week old female balb/c mice followed by an injection of sodium arsenite 0.87 mg/kg i.p. at 10 minutes. Again a protective effect was observed with 0 deaths in 18 mice vs eight deaths in 21 mice (38%; p < 005). Seventeen additional mice were given an injection of 0.87 mg/kg i.p. of sodium arsenite. After 30 minutes, all mice became symptomatic whereupon antisera 0.1 cc i.p. was given. The one day mortality (2/17, 12% was possibly lower than the combined control mortality (17/50, 34%; p < 0.07). There was no change in mortality noted when antisera was administered to mice acutely exposed to 5 mg/kg HgCl2.

Original languageEnglish (US)
Pages (from-to)59-70
Number of pages12
JournalClinical Toxicology
Volume29
Issue number1
DOIs
StatePublished - Jan 1 1991

Fingerprint

Arsenic Poisoning
Arsenic
Immunotherapy
Arsanilic Acid
Immune Sera
Ovalbumin
Mortality
Injections
Mercuric Chloride
Serum
Antibodies
Toxicity
sodium arsenite
Carrier Proteins
Copolymers
Radioimmunoassay

Keywords

  • Arsanilic antibody
  • Arsenic poisoning
  • Arsenite
  • Immunotherapy
  • Mouse
  • Sodium

ASJC Scopus subject areas

  • Toxicology

Cite this

Leikin, J. B., Leikin, R. G., Evans, M. A., Wiener, S., & Hryhorczuk, D. O. (1991). Immunotherapy in acute arsenic poisoning. Clinical Toxicology, 29(1), 59-70. https://doi.org/10.3109/15563659109038598
Leikin, Jerrold B. ; Leikin, Robin G ; Evans, Michael A. ; Wiener, Stanley ; Hryhorczuk, Daniel O. / Immunotherapy in acute arsenic poisoning. In: Clinical Toxicology. 1991 ; Vol. 29, No. 1. pp. 59-70.
@article{dfb90dfa7a0d497792ed5b9cf1122cca,
title = "Immunotherapy in acute arsenic poisoning",
abstract = "We investigated the use of immunotherapy on the treatment of sodium arsenite toxicity. Female balb/c mice injected with arsanilic acid conjugated to a carrier protein (ovalbumin) were shown to produce antibodies (arsenic reactive serum, ARS) reactive with arsanilic acid and sodium arsenite. Serum was tested for anti-ARS antibodies using a solid phase radioimmunoassay. The antisera bound to ARS conjugated to the synthetic copolymer glutamic acid60 tyrosine30 when diluted as high as 1:4096. Following multiple injections of 100 μg of arsanilic acid - ovalbumin compound, mortality on injection with sodium arsenite 0.87 mg/kg i.p. one week later decreased to 0 deaths in 22 pretreated mice vs 9 deaths in 29 untreated mice (31{\%} mortality; p < 005). No decrease in mortality was noted at higher challenges (1.15 mg/kg) of sodium arsenite. Antisera from pretreated mice was injected 0.1 cc i.p. into 12 week old female balb/c mice followed by an injection of sodium arsenite 0.87 mg/kg i.p. at 10 minutes. Again a protective effect was observed with 0 deaths in 18 mice vs eight deaths in 21 mice (38{\%}; p < 005). Seventeen additional mice were given an injection of 0.87 mg/kg i.p. of sodium arsenite. After 30 minutes, all mice became symptomatic whereupon antisera 0.1 cc i.p. was given. The one day mortality (2/17, 12{\%} was possibly lower than the combined control mortality (17/50, 34{\%}; p < 0.07). There was no change in mortality noted when antisera was administered to mice acutely exposed to 5 mg/kg HgCl2.",
keywords = "Arsanilic antibody, Arsenic poisoning, Arsenite, Immunotherapy, Mouse, Sodium",
author = "Leikin, {Jerrold B.} and Leikin, {Robin G} and Evans, {Michael A.} and Stanley Wiener and Hryhorczuk, {Daniel O.}",
year = "1991",
month = "1",
day = "1",
doi = "10.3109/15563659109038598",
language = "English (US)",
volume = "29",
pages = "59--70",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "1",

}

Leikin, JB, Leikin, RG, Evans, MA, Wiener, S & Hryhorczuk, DO 1991, 'Immunotherapy in acute arsenic poisoning', Clinical Toxicology, vol. 29, no. 1, pp. 59-70. https://doi.org/10.3109/15563659109038598

Immunotherapy in acute arsenic poisoning. / Leikin, Jerrold B.; Leikin, Robin G; Evans, Michael A.; Wiener, Stanley; Hryhorczuk, Daniel O.

In: Clinical Toxicology, Vol. 29, No. 1, 01.01.1991, p. 59-70.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunotherapy in acute arsenic poisoning

AU - Leikin, Jerrold B.

AU - Leikin, Robin G

AU - Evans, Michael A.

AU - Wiener, Stanley

AU - Hryhorczuk, Daniel O.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - We investigated the use of immunotherapy on the treatment of sodium arsenite toxicity. Female balb/c mice injected with arsanilic acid conjugated to a carrier protein (ovalbumin) were shown to produce antibodies (arsenic reactive serum, ARS) reactive with arsanilic acid and sodium arsenite. Serum was tested for anti-ARS antibodies using a solid phase radioimmunoassay. The antisera bound to ARS conjugated to the synthetic copolymer glutamic acid60 tyrosine30 when diluted as high as 1:4096. Following multiple injections of 100 μg of arsanilic acid - ovalbumin compound, mortality on injection with sodium arsenite 0.87 mg/kg i.p. one week later decreased to 0 deaths in 22 pretreated mice vs 9 deaths in 29 untreated mice (31% mortality; p < 005). No decrease in mortality was noted at higher challenges (1.15 mg/kg) of sodium arsenite. Antisera from pretreated mice was injected 0.1 cc i.p. into 12 week old female balb/c mice followed by an injection of sodium arsenite 0.87 mg/kg i.p. at 10 minutes. Again a protective effect was observed with 0 deaths in 18 mice vs eight deaths in 21 mice (38%; p < 005). Seventeen additional mice were given an injection of 0.87 mg/kg i.p. of sodium arsenite. After 30 minutes, all mice became symptomatic whereupon antisera 0.1 cc i.p. was given. The one day mortality (2/17, 12% was possibly lower than the combined control mortality (17/50, 34%; p < 0.07). There was no change in mortality noted when antisera was administered to mice acutely exposed to 5 mg/kg HgCl2.

AB - We investigated the use of immunotherapy on the treatment of sodium arsenite toxicity. Female balb/c mice injected with arsanilic acid conjugated to a carrier protein (ovalbumin) were shown to produce antibodies (arsenic reactive serum, ARS) reactive with arsanilic acid and sodium arsenite. Serum was tested for anti-ARS antibodies using a solid phase radioimmunoassay. The antisera bound to ARS conjugated to the synthetic copolymer glutamic acid60 tyrosine30 when diluted as high as 1:4096. Following multiple injections of 100 μg of arsanilic acid - ovalbumin compound, mortality on injection with sodium arsenite 0.87 mg/kg i.p. one week later decreased to 0 deaths in 22 pretreated mice vs 9 deaths in 29 untreated mice (31% mortality; p < 005). No decrease in mortality was noted at higher challenges (1.15 mg/kg) of sodium arsenite. Antisera from pretreated mice was injected 0.1 cc i.p. into 12 week old female balb/c mice followed by an injection of sodium arsenite 0.87 mg/kg i.p. at 10 minutes. Again a protective effect was observed with 0 deaths in 18 mice vs eight deaths in 21 mice (38%; p < 005). Seventeen additional mice were given an injection of 0.87 mg/kg i.p. of sodium arsenite. After 30 minutes, all mice became symptomatic whereupon antisera 0.1 cc i.p. was given. The one day mortality (2/17, 12% was possibly lower than the combined control mortality (17/50, 34%; p < 0.07). There was no change in mortality noted when antisera was administered to mice acutely exposed to 5 mg/kg HgCl2.

KW - Arsanilic antibody

KW - Arsenic poisoning

KW - Arsenite

KW - Immunotherapy

KW - Mouse

KW - Sodium

UR - http://www.scopus.com/inward/record.url?scp=0026013303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026013303&partnerID=8YFLogxK

U2 - 10.3109/15563659109038598

DO - 10.3109/15563659109038598

M3 - Article

VL - 29

SP - 59

EP - 70

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 1

ER -

Leikin JB, Leikin RG, Evans MA, Wiener S, Hryhorczuk DO. Immunotherapy in acute arsenic poisoning. Clinical Toxicology. 1991 Jan 1;29(1):59-70. https://doi.org/10.3109/15563659109038598